Silo Pharma Inc. (NASDAQ: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' AMD AI Developer Program. The program provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community. This acceptance is expected to accelerate the development, testing, optimization, and deployment of QwikAgents' AI agent platform across consumer and enterprise applications.
QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding, and workflow automation. According to the company, participation in the AMD AI Developer Program is expected to support platform performance, agent reliability, and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses, and enterprise customers.
The AMD AI Developer Program is designed to equip developers with the resources needed to build and optimize AI applications on AMD hardware. By joining the program, QwikAgents gains early access to AMD's latest AI technologies and a community of developers. This collaboration could potentially enhance the efficiency and capabilities of QwikAgents' platform, making it more competitive in the rapidly growing AI agent market.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The acceptance of QwikAgents into the AMD AI Developer Program marks a strategic move for Silo Pharma, expanding its footprint beyond biopharmaceuticals into the AI technology sector. This diversification could provide new revenue streams and technological synergies. For the AI industry, the partnership underscores the growing importance of specialized AI platforms that can automate complex tasks, potentially increasing productivity for businesses and individuals.
As AI agents become more prevalent, platforms like QwikAgents that leverage powerful hardware and developer ecosystems may gain a competitive edge. The AMD AI Developer Program provides the infrastructure needed to optimize AI models for performance and scalability, which is critical for real-world applications. This development could influence how AI agent platforms are developed and deployed, setting a precedent for collaborations between hardware providers and AI startups.
For more information about Silo Pharma, visit silopharma.com. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
